Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:13:59.964Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:13:59.964Z.
Quote observation: 2026-10-06T19:10:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 27d43c4ad977ebfb60fd4d152ccd3ecb2c1433393c1fe13b1b38eb8ac2c2edf2
FORWARD PE RATIO
N/A
Utah Medical Products, Inc.
Market Cap
$235.69M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Utah Medical Products, Inc. (UTMD) | $235.69M | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $235.95M | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.23M | N/A |
| Invivyd, Inc. (IVVD)vs › | $236.83M | N/A |
| InflaRx N.V. (IFRX)vs › | $234.20M | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $237.72M | N/A |
| High Tide Inc. (HITI)vs › | $238.13M | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $232.74M | 1.91 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.12M | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $242.35M | N/A |
Trailing P/E
22.6
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
